Krystal Biotech Inc (NAS:KRYS)
$ 156.35 -2.65 (-1.67%) Market Cap: 4.47 Bil Enterprise Value: 4.01 Bil PE Ratio: 83.16 PB Ratio: 5.58 GF Score: 38/100

Krystal Biotech Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 03:20PM GMT
Release Date Price: $65.47 (+0.11%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

All right, everyone. I'd like to thank everyone for joining us today at the Goldman Sachs Global Healthcare Conference, and we're so pleased to be joined by Krish Krishnan from Krystal Biotech to give us a good update on where things are, where things headed into, there's really kind of, no pun intended, pivotal year for the company.

Questions & Answers

Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

So Krish, let's start at a big picture level. Why don't we walk through Krystal's herpes simplex virus or HSV gene therapy platform, including a rundown of both pipeline candidates and ongoing clinical studies.

Krish S. Krishnan
Krystal Biotech, Inc. - Chairman, President & CEO

Sure. First, thanks for having me. Thanks for having the company. So Krystal's HSV-1 is a DNA virus with many favorable properties as a delivery vector for therapeutic genes, including other exogenous generic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot